Oncology Practice will be on site this coming week at the 2017 Genitourinary Cancers Symposium in Orlando with the latest on treatment of prostate, kidney, testicular, and urothelial cancers. Look for coverage of the best clinical presentations at the conference, hosted by the American Society of Clinical Oncology, ASTRO, and the Society of Urologic Oncology, including the following and more, beginning Thursday, Feb. 16:
- Outcomes of PD-1/PD-L1 responders who discontinued therapy for immune-related adverse events: Results of a cohort of patients with metastatic renal cell carcinoma. First author: Rana McKay, MD.
- Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. First author: Lisa Derosa, MD.
- Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy. First author: Guru Sonpavde, MD.
- Evolution of circulating tumor DNA profile from first-line to second-line therapy in metastatic renal cell carcinoma.
- First author: Sumanta Pal, MD.
- Clinical significance of AR mRNA quantification from circulating tumor cells in men with metastatic castration-resistant prostate cancer treated with abiraterone (Abi) or enzalutamide (Enza). First author: John Silberstein, MD.
- Adjuvant androgen deprivation versus mitoxantrone plus prednisone plus ADT in high-risk prostate cancer patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124. First author: L. Glode, MD.